Somatogen (SMTG) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jeff Clegg who wrote (355)	1/10/1998 4:53:00 PM
From: Bharat H. Barai	Read Replies (1) of 442

It is mu understanding that part A is completed now. They are trying to see if CNS complications decrease when Optro is used versus whole blood. The study indirectly but discreetly studies the safety and the tolerability of the product. To me that was the most important issue. It appears that that has been shown. The main use of present generation Optro will be in emergency situation. The next generation molecules do not have vaso spastic side effects and can be given in awake individuals. That will be key to success. What will happen to stock price is anybody's guess in this market. Logically it should support and stabilize the price to a higher level. Logic does not always work in 29 yrs old MBA kids, who are playing with other people's money as "money managers". Instead of becoming an instrument of savings, growth and source of capital, stock market has become "Las Vegas". May be they should move all the stock exchanges to Las Vegas. B.H. Barai MD

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next